| Assessment Status | Awaiting response from Applicant | |
| HTA ID | 22058 | |
| Drug | Tucatinib | |
| Brand | Tukysa® | |
| Indication | In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. | |
| Rapid review commissioned | 23/08/2022 | |
| Rapid review completed | 20/09/2022 | |
| Full pharmacoeconomic assessment commissioned by HSE | 28/09/2022 | |
| Pre-submission consultation with Applicant | 12/12/2023 | |
| Full submission received from Applicant | 14/03/2024 | |
| Assessment process on hold as updated submission required | 06/12/2024 | |
| Updated submission received | 10/03/2025 | |
| Preliminary Review sent to Applicant | 10/04/2025 |
